Promising observations from a phase Ib trial using the gemcitabine pro-drug NUC-1031, designed to overcome tumor mechanisms of drug resistance, could not be supported by efficacy testing using the cytidine deaminase (CDA)-high CCA patient-derived xenograft (PDX) model [24,25]. Here, CDA is linked to neoplasm.